1-6 of 6
Lawrence H. Schwartz
Close
Sort by
Journal Articles

Evaluation of Volumetric Lymph Node Measurements in Cutaneous T-Cell Lymphoma Patients Enrolled in the Mavoric Trial: An Interim Analysis

Lauren Fahmy, Hye Ryung Yang, Bradley Kwinta, Volkan Beylergil, Celine M Schreidah, Lawrence H. Schwartz, Larisa J Geskin
Journal: Blood
Blood (2022) 140 (Supplement 1): 3700.
https://doi.org/10.1182/blood-2022-163711
Published: 2022
Journal Articles

Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]

Amy S. Ruppert, PhD, Levi D. Pederson, MS, Michael V. Knopp, MD PhD, David Poon, BS, Jun Zhang, PhD, Brad S. Kahl, MD, Jonathan W. Friedberg, MD MSSc, Lawrence H. Schwartz, MD, Wyndham H. Wilson, MD PhD, John P. Leonard, MD, Nancy L. Bartlett, MD, Heiko Schöder, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50.
https://doi.org/10.1182/blood-2020-139979
Published: 2020
Journal Articles

Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial

Clinical Trials & Observations
Heiko Schöder, Mei-Yin C. Polley, Michael V. Knopp, Nathan Hall, Lale Kostakoglu, Jun Zhang, Howard R. Higley, Gary Kelloff, Heshan Liu, Andrew D. Zelenetz, Bruce D. Cheson, Nina Wagner-Johnston, Brad S. Kahl, Jonathan W. Friedberg, Eric D. Hsi, John P. Leonard, Lawrence H. Schwartz, Wyndham H. Wilson, Nancy L. Bartlett
Journal: Blood
Blood (2020) 135 (25): 2224–2234.
https://doi.org/10.1182/blood.2019003277
Published: 2020
Includes: Supplemental data
Journal Articles

PD-1 Blockade after Epigenetic Therapy in Patients with Relapsed or Refractory Hodgkin Lymphoma: Higher-Than-Expected Rate of Complete Responses

Lorenzo Falchi, MD, Ahmed Sawas, MD, Changchun Deng, MD PhD, Jennifer E Amengual, MD, Emily Lichtenstein, RN, Karen Khan, BSN, Lawrence H. Schwartz, MD, Owen A. O'Connor, MD PhD
Journal: Blood
Blood (2016) 128 (22): 2999.
https://doi.org/10.1182/blood.V128.22.2999.2999
Published: 2016
Journal Articles

Doxorubicin, vinblastine, and gemcitabine (CALGB 50203) for stage I/II nonbulky Hodgkin lymphoma: pretreatment prognostic factors and interim PET

Clinical Trials & Observations
David J. Straus, Jeffrey L. Johnson, Ann S. LaCasce, Nancy L. Bartlett, Lale Kostakoglu, Eric D. Hsi, Heiko Schöder, Nathan C. Hall, Sin-Ho Jung, George P. Canellos, Lawrence H. Schwartz, Ronald W. Takvorian, Malik E. Juweid, Bruce D. Cheson, for Cancer and Leukemia Group B
Journal: Blood
Blood (2011) 117 (20): 5314–5320.
https://doi.org/10.1182/blood-2010-10-314260
Published: 2011
Journal Articles

Validation of the International Harmonization Project (IHP) Guidelines in Early Stage Hodgkin Lymphoma (HL) Treated with Adriamycin, Vinblastine and Gemcitabine (AVG) (CALGB 50203): Early Results.

Lale Kostakoglu, MD, MPH, David J. Straus, MD, Heiko Schöder, MD, Ann S. LaCasce, MD, Nancy L Bartlett, MD, Nathan Hall, MD, PhD, Jeffrey L Johnson, PhD, Sin-Ho Jung, PhD, George P. Canellos, MD, Lawrence H Schwartz, MD, Bruce D. Cheson, MD
Journal: Blood
Blood (2008) 112 (11): 1460.
https://doi.org/10.1182/blood.V112.11.1460.1460
Published: 2008